Keywords
GLP-1 receptor agonists
Weight regain
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the impact of discontinuation of therapies based on glucagon-like peptide-1 (GLP-1) receptor agonists on weight regain and the maintenance of metabolic benefits in the treatment of obesity. Literature review: Incretin-based therapies, especially GLP-1 receptor agonists and dual GLP-1/GIP agonists, represent a significant advance in the pharmacological treatment of obesity, promoting substantial weight loss and improvement in cardiometabolic parameters. However, evidence indicates that discontinuation of these therapies is frequently associated with weight regain. In addition to increased body weight, there is a tendency toward partial reversal of previously achieved metabolic improvements, including changes in glycemic control, lipid profile, and blood pressure. In this context, strategies such as maintaining lifestyle modifications, regular physical activity, and continuous clinical follow-up may help partially mitigate weight regain after discontinuation of pharmacological treatment. Final considerations: Recognizing obesity as a chronic condition reinforces the need for sustained and individualized therapeutic approaches, with a focus on preventing weight regain and preserving the metabolic benefits achieved during treatment.
References
ABDULLAH BIA, et al. A comprehensive review on weight gain following discontinuation of glucagon-like peptide-1 receptor agonists for obesity. Journal of Obesity, 2024; 8056440.
ALEXANDER GC, et al. Weight changes from glucagon-like peptide-1 receptor agonist use and discontinuation: a retrospective cohort study. Obesity, 2026; 34(2):482-490.
ARD J, et al. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide-1 receptor agonists. Advances in Therapy, 2021; 38(6):2821-2839.
BERG S, et al. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review. 2025.
BUDINI B, et al. Trajectory of weight regain after discontinuation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. 2025.
CHOE HJ, et al. Metabolic consequences of glucagon-like peptide-1 receptor agonist shortage: deterioration of glycemic control in type 2 diabetes. Endocrinology and Metabolism, 2025.
JENSEN SBK, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. eClinicalMedicine, 2024; 69:102475.
JIA TI, et al. Analysis of the long-term impact of glucagon-like peptide-1 receptor agonists for control of obesity and obesity-related comorbidities: a meta-analysis. Surgical Endoscopy, 2025; 39:8580-8589.
JORDAN G, et al. Weight loss pharmacotherapy: current and future therapies. Gastrointestinal Endoscopy Clinics of North America, 2024; 34(4):591-608.
KOLLI RT, et al. Rebound or retention: a meta-analysis of weight regain after the discontinuation of glucagon-like peptide-1 (GLP-1) receptor agonists and other anti-obesity drugs. Cureus, 2025; 17(10):e94926.
LOCATELLI JC et al. Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition? Diabetes Care, 2024; 47(10):1718-1730.
MOZAFFARIAN D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Obesity Pillars, 2025; 15:100181.
REISS AB, et al. Weight reduction with GLP-1 agonists and paths for discontinuation while maintaining weight loss. Biomolecules, 2025; 15(3):408.
STOLL F, et al. Tackling suboptimal clinical response after metabolic bariatric surgery: impact of tirzepatide on weight loss and body composition. Obesity Research & Clinical Practice, 2025; 19:63-69.
TZANG CC, et al. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. eClinicalMedicine, 2025; 90:103680.
VAN BAAK MA, MARIMAN ECM. Physiology of weight regain after weight loss: latest insights. Current Obesity Reports, 2025; 14:28.
WEST S, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ, 2026; 392:e085304.
WILDING JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022; 24:1553-1564.
WU H, et al. Trajectory of body weight after drug discontinuation in the treatment of anti-obesity medications. BMC Medicine, 2025; 23:398.
ZHANG Y, et al. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovascular Diabetology, 2022; 21:232.